

- B,
99. The isolated polypeptide of claim 95, wherein said polypeptide is part of a fusion protein.
 100. The isolated polypeptide of claim 95, which is produced in a recombinant cell.
 101. The isolated polypeptide of claim 100, wherein said recombinant cell is bacterial.
 102. The isolated polypeptide of claim 95, together with a pharmaceutically acceptable carrier or excipient.
 103. An isolated polypeptide comprising an amino acid sequence at least 90% identical to Val (123) - Ser (208) of SEQ ID NO:2.
 104. The isolated polypeptide of claim 103, comprising an amino acid sequence at least 95% identical to Val (123) - Ser (208) of SEQ ID NO:2.
 105. The isolated polypeptide of claim 104, comprising an amino acid sequence at least 97% identical to Val (123) - Ser (208) of SEQ ID NO:2.
 106. The isolated polypeptide of claim 103, having a Met residue at the N-terminus of said amino acid sequence.

B₁

107. The isolated polypeptide of claim 103, wherein said polypeptide is part of a fusion protein.
108. The isolated polypeptide of claim 103, which is produced in a recombinant cell.
109. The isolated polypeptide of claim 108, wherein said recombinant cell is bacterial.
110. The isolated polypeptide of claim 103, together with a pharmaceutically acceptable carrier or excipient.
111. An isolated polypeptide comprising an amino acid sequence at least 90% identical to Glu (104) - Ser (208) of SEQ ID NO:2.
112. The isolated polypeptide of claim 111, comprising an amino acid sequence at least 95% identical to Glu (104) - Ser (208) of SEQ ID NO:2.
113. The isolated polypeptide of claim 112, comprising an amino acid sequence at least 97% identical to Glu (104) - Ser (208) of SEQ ID NO:2.
114. The isolated polypeptide of claim 111, having a Met residue at the N-terminus of said amino acid sequence.
115. The isolated polypeptide of claim 111, wherein said polypeptide is part of a fusion protein.

81

116. The isolated polypeptide of claim 111, which is produced in a recombinant cell.
117. The isolated polypeptide of claim 116, wherein said recombinant cell is bacterial.
118. The isolated polypeptide of claim 111, together with a pharmaceutically acceptable carrier or excipient.
119. An isolated polypeptide comprising an amino acid sequence at least 90% identical to Val (77) - Ser (208) of SEQ ID NO:2.
120. The isolated polypeptide of claim 119, comprising an amino acid sequence at least 95% identical to Val (77) - Ser (208) of SEQ ID NO:2.
121. The isolated polypeptide of claim 120, comprising an amino acid sequence at least 97% identical to Val (77) - Ser (208) of SEQ ID NO:2.
122. The isolated polypeptide of claim 119, having a Met residue at the N-terminus of said amino acid sequence.
123. The isolated polypeptide of claim 119, wherein said polypeptide is part of a fusion protein.

bl

124. The isolated polypeptide of claim 119, which is produced in a recombinant cell.
125. The isolated polypeptide of claim 124, wherein said recombinant cell is bacterial.
126. The isolated polypeptide of claim 119, together with a pharmaceutically acceptable carrier or excipient.
127. An isolated polypeptide comprising an amino acid sequence at least 90% identical to Ser (69) - Ser (208) of SEQ ID NO:2.
128. The isolated polypeptide of claim 127, comprising an amino acid sequence at least 95% identical to Ser (69) - Ser (208) of SEQ ID NO:2.
129. The isolated polypeptide of claim 128, comprising an amino acid sequence at least 97% identical to Ser (69) - Ser (208) of SEQ ID NO:2.
130. The isolated polypeptide of claim 127, 128 or 129, having a Met residue at the N-terminus of said amino acid sequence.
131. The isolated polypeptide of claim 127, 128 or 129, wherein said polypeptide is part of a fusion protein.

B1

132. The isolated polypeptide of claim 127, 128 or 129, which is produced in a recombinant cell.
133. The isolated polypeptide of claim 132, wherein said recombinant cell is bacterial.
134. The isolated polypeptide of claim 127, 128 or 129, together with a pharmaceutically acceptable carrier or excipient.
135. An isolated polypeptide comprising an amino acid sequence at least 90% identical to Ala (63) - Ser (208) of SEQ ID NO:2.
136. The isolated polypeptide of claim 135, comprising an amino acid sequence at least 95% identical to Ala (63) - Ser (208) of SEQ ID NO:2.
137. The isolated polypeptide of claim 136, comprising an amino acid sequence at least 97% identical to Ala (63) - Ser (208) of SEQ ID NO:2.
138. The isolated polypeptide of claim 135, 136, or 137, having a Met residue at the N-terminus of said amino acid sequence.
139. The isolated polypeptide of claim 135, 136, or 137, wherein said polypeptide is part of a fusion protein.

B₁

140. The isolated polypeptide of claim 135, 136, or 137, which is produced in a recombinant cell.
141. The isolated polypeptide of claim 140, wherein said recombinant cell is bacterial.
142. The isolated polypeptide of claim 135, 136, or 137, together with a pharmaceutically acceptable carrier or excipient.
143. An isolated polypeptide comprising an amino acid sequence at least 90% identical to Cys (37) - Ser (208) of SEQ ID NO:2.
144. The isolated polypeptide of claim 143, comprising an amino acid sequence at least 95% identical to Cys (37) - Ser (208) of SEQ ID NO:2.
145. The isolated polypeptide of claim 144, comprising an amino acid sequence at least 97% identical to Cys (37) - Ser (208) of SEQ ID NO:2.
146. The isolated polypeptide of claim 143, 144, or 145, having a Met residue at the N-terminus of said amino acid sequence.
147. The isolated polypeptide of claim 143, 144, or 145, wherein said polypeptide is part of a fusion protein.

B1

148. The isolated polypeptide of claim 143, 144, or 145, which is produced in a recombinant cell.
149. The isolated polypeptide of claim 148, wherein said recombinant cell is bacterial.
150. The isolated polypeptide of claim 143, 144, or 145, together with a pharmaceutically acceptable carrier or excipient.
151. An isolated polypeptide comprising an amino acid sequence at least 90% identical to Thr (36) - Ser (208) of SEQ ID NO:2.
152. The isolated polypeptide of claim 151, comprising an amino acid sequence at least 95% identical to Thr(36) - Ser (208) of SEQ ID NO:2.
153. The isolated polypeptide of claim 152, comprising an amino acid sequence at least 97% identical to Thr(36) - Ser (208) of SEQ ID NO:2.
154. The isolated polypeptide of claim 151, 152, or 153 having a Met residue at the N-terminus of said amino acid sequence.
155. The isolated polypeptide of claim 151, 152, or 153 wherein said polypeptide is part of a fusion protein.

B

156. The isolated polypeptide of claim 151, 152, or 153 which is produced in a recombinant cell.
157. The isolated polypeptide of claim 156, wherein said recombinant cell is bacterial.
158. The isolated polypeptide of claim 151, 152, or 153 together with a pharmaceutically acceptable carrier or excipient.
159. An isolated polypeptide comprising an amino acid sequence at least 90% identical to Trp (2) - Ser (208) of SEQ ID NO:2.
160. The isolated polypeptide of claim 159, comprising an amino acid sequence at least 95% identical to Trp (2) - Ser (208) of SEQ ID NO:2.
161. The isolated polypeptide of claim 160, comprising an amino acid sequence at least 97% identical to Trp (2) - Ser (208) of SEQ ID NO:2.
162. The isolated polypeptide of claim 159, 160, or 161, having a Met residue at the N-terminus of said amino acid sequence.
163. The isolated polypeptide of claim 159, 160, or 161, wherein said polypeptide is part of a fusion protein.

21

164. The isolated polypeptide of claim 159, 160, or 161, which is produced in a recombinant cell.
165. The isolated polypeptide of claim 164, wherein said recombinant cell is bacterial.
166. The isolated polypeptide of claim 159, 160, or 161, together with a pharmaceutically acceptable carrier or excipient.
167. An isolated polypeptide comprising an amino acid sequence at least 90% identical to Ala (63) - Lys (153) of SEQ ID NO:2.
168. The isolated polypeptide of claim 167, comprising an amino acid sequence at least 95% identical to Ala (63) - Lys (153) of SEQ ID NO:2.
169. The isolated polypeptide of claim 168, comprising an amino acid sequence at least 97% identical to Ala (63) - Lys (153) of SEQ ID NO:2.
170. The isolated polypeptide of claim 167, 168, or 169, having a Met residue at the N-terminus of said amino acid sequence.
171. The isolated polypeptide of claim 167, 168, or 169, wherein said polypeptide is part of a fusion protein.

B₁

172. The isolated polypeptide of claim 167, 168, or 169, which is produced in a recombinant cell.
173. The isolated polypeptide of claim 172, wherein said recombinant cell is bacterial.
174. The isolated polypeptide of claim 167, 168, or 169, together with a pharmaceutically acceptable carrier or excipient.
175. An isolated polypeptide comprising an amino acid sequence at least 90% identical to Thr (36) - Lys (153) of SEQ ID NO:2.
176. The isolated polypeptide of claim 175, comprising an amino acid sequence at least 95% identical to of Thr (36) - Lys (153) of SEQ ID NO:2.
177. The isolated polypeptide of claim 176, comprising an amino acid sequence at least 97% identical to Thr (36) - Lys (153) of SEQ ID NO:2.
178. The isolated polypeptide of claim 175, having a Met residue at the N-terminus of said amino acid sequence.
179. The isolated polypeptide of claim 175, wherein said polypeptide is part of a fusion protein.